Latest Pharma Insights
Estée Lauder Plans To Acquire Entire Stake Of Indian Brand Forest Essentials
The Estee Lauder Companies Inc. plans to acquire New Delhi-based luxury Ayurvedic beauty brand Forest Essentials in a transaction subject to regulatory approvals and that is expected to close in the second half of the year.
HBW Insight - March 9, 2026
The Estee Lauder Companies Inc. plans to acquire New Delhi-based luxury Ayurvedic beauty brand Forest Essentials in a transaction subject to regulatory approvals and that is expected to close in the second half of the year.
HBW Insight - March 9, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: smaller companies consider European expansion under MFN; Pfizer CEO on FDA vaccine decisions; what does big pharma want from CRDMOs in AI age; neuroscience funding poised for comeback; and UCB’s big China deal.
Scrip - March 9, 2026
In this week's episode: smaller companies consider European expansion under MFN; Pfizer CEO on FDA vaccine decisions; what does big pharma want from CRDMOs in AI age; neuroscience funding poised for comeback; and UCB’s big China deal.
Scrip - March 9, 2026
PDUFA VIII: US FDA Willing To Risk One-Time Potential Revenue Reduction In Five-Year Cycle
The agency offered to commission a third-party study of efficiency, workload and other factors to determine whether the base PDUFA revenue should be lowered mid-program cycle.
HBW Insight - March 9, 2026
The agency offered to commission a third-party study of efficiency, workload and other factors to determine whether the base PDUFA revenue should be lowered mid-program cycle.
HBW Insight - March 9, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: smaller companies consider European expansion under MFN; Pfizer CEO on FDA vaccine decisions; what does big pharma want from CRDMOs in AI age; neuroscience funding poised for comeback; and UCB’s big China deal.
Scrip - March 9, 2026
In this week's episode: smaller companies consider European expansion under MFN; Pfizer CEO on FDA vaccine decisions; what does big pharma want from CRDMOs in AI age; neuroscience funding poised for comeback; and UCB’s big China deal.
Scrip - March 9, 2026
Global Medtech Guidance Tracker: February 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.
Medtech Insight - March 6, 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.
Medtech Insight - March 6, 2026
Curve Biosciences Targets Liver Disease With ‘Whole-Body Intelligence’ Platform
Curve Biosciences is developing a technology that analyzes signals from blood and organs to monitor the progression of chronic disease. The first product is a blood test to monitor patients with liver cirrhosis at risk for liver cancer, the second for MASH.
Medtech Insight - March 6, 2026
Curve Biosciences is developing a technology that analyzes signals from blood and organs to monitor the progression of chronic disease. The first product is a blood test to monitor patients with liver cirrhosis at risk for liver cancer, the second for MASH.
Medtech Insight - March 6, 2026
FDA And Industry Agree To Hiring Levels Based On Prior MDUFA Commitment Letter
During MDUFA negotiations held Feb. 11, the medtech industry agreed to a proposal from the FDA to base its hiring commitments on MDUFA IV.
Medtech Insight - March 6, 2026
During MDUFA negotiations held Feb. 11, the medtech industry agreed to a proposal from the FDA to base its hiring commitments on MDUFA IV.
Medtech Insight - March 6, 2026
NVision Takes Quantum Imaging To Cambridge, Targets 20 Global Sites In 2026
NVision is pursuing regulatory clearance in the US, with trials launching across the US, Europe and Asia. In Europe, it is starting with Germany, Denmark, the UK and Italy before seeking broader EMA approval.
Medtech Insight - March 6, 2026
NVision is pursuing regulatory clearance in the US, with trials launching across the US, Europe and Asia. In Europe, it is starting with Germany, Denmark, the UK and Italy before seeking broader EMA approval.
Medtech Insight - March 6, 2026
Estée Lauder Plans To Acquire Entire Stake Of Indian Brand Forest Essentials
The Estee Lauder Companies Inc. plans to acquire New Delhi-based luxury Ayurvedic beauty brand Forest Essentials in a transaction subject to regulatory approvals and that is expected to close in the second half of the year.
HBW Insight - March 9, 2026
The Estee Lauder Companies Inc. plans to acquire New Delhi-based luxury Ayurvedic beauty brand Forest Essentials in a transaction subject to regulatory approvals and that is expected to close in the second half of the year.
HBW Insight - March 9, 2026
PDUFA VIII: US FDA Willing To Risk One-Time Potential Revenue Reduction In Five-Year Cycle
The agency offered to commission a third-party study of efficiency, workload and other factors to determine whether the base PDUFA revenue should be lowered mid-program cycle.
HBW Insight - March 9, 2026
The agency offered to commission a third-party study of efficiency, workload and other factors to determine whether the base PDUFA revenue should be lowered mid-program cycle.
HBW Insight - March 9, 2026
Sandoz Moves In On Canadian And Brazilian Semaglutide Opportunity
Sandoz says GLP-1s represent a long-term growth opportunity but warns the off-patent market will take time to develop, with early launches potentially coming in Canada and Brazil as the company tests supply dynamics and regulatory timelines.
Generics Bulletin - March 6, 2026
Sandoz says GLP-1s represent a long-term growth opportunity but warns the off-patent market will take time to develop, with early launches potentially coming in Canada and Brazil as the company tests supply dynamics and regulatory timelines.
Generics Bulletin - March 6, 2026
Affordable Medicines To Be Key Driver For Amneal In 2026 As Specialty Takes Back Seat
Even Amneal, a prominent off-patent player, is not immune to generic competition, as its Parkinson’s disease drug Rytary is expected to take a hit.
Generics Bulletin - March 6, 2026
Even Amneal, a prominent off-patent player, is not immune to generic competition, as its Parkinson’s disease drug Rytary is expected to take a hit.
Generics Bulletin - March 6, 2026
Aspen Aiming ‘To Be In The Mix’ As Generic Semaglutide Reaches Canada Soon
Aspen Pharmacare is targeting early launches of generic semaglutide as patents begin to expire, aiming to be among the first entrants in Canada’s emerging market for GLP-1 rivals and using the approval as a springboard into emerging markets.
Generics Bulletin - March 6, 2026
Aspen Pharmacare is targeting early launches of generic semaglutide as patents begin to expire, aiming to be among the first entrants in Canada’s emerging market for GLP-1 rivals and using the approval as a springboard into emerging markets.
Generics Bulletin - March 6, 2026
The Autonomous Lab: Part 1
In this two-part series, In Vivo examines who is building the autonomous lab, what architectural and business model choices they are making, and what the implications are for drug discovery organizations, external R&D partnerships and the workforce that will be asked to operate these systems.
In Vivo - March 5, 2026
In this two-part series, In Vivo examines who is building the autonomous lab, what architectural and business model choices they are making, and what the implications are for drug discovery organizations, external R&D partnerships and the workforce that will be asked to operate these systems.
In Vivo - March 5, 2026